Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
2001
Size (employees)
17 (est)-26%
Chiasma was founded in 2001 and is headquartered in Waltham, US

Key People at Chiasma

Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member

Chiasma Office Locations

Chiasma has offices in Waltham and Ness Ziona
Waltham, US (HQ)
250 275 Wyman St
Ness Ziona, IL
5 Golda Me'ir St

Chiasma Data and Metrics

Chiasma Financial Metrics

USD

Net income (Q1, 2017)

(7 m)

EBIT (Q1, 2017)

(7.1 m)

Market capitalization (21-Jul-2017)

34.7 m

Cash (31-Mar-2017)

19 m
Chiasma's current market capitalization is $34.7 m.
USDFY, 2015FY, 2016

R&D expense

19 m31.3 m

Operating expense total

35.4 m61.3 m

EBIT

(35.4 m)(61.3 m)

Pre tax profit

(60.8 m)

Income tax expense

161 k347 k

Net Income

(35.9 m)(61.1 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

4.2 m4.4 m7.2 m14.8 m4.5 m4.7 m

General and administrative expense

2.5 m

Operating expense total

4.2 m4.4 m7.2 m14.8 m4.5 m7.1 m

EBIT

(7.6 m)(9.2 m)(17.2 m)(26.7 m)(9.4 m)(7.1 m)

Pre tax profit

(17.1 m)(26.6 m)(9.3 m)(7 m)

Income tax expense

68.7 k71.5 k89 k76 k73 k65 k

Net Income

(7.8 m)(9.4 m)(17.2 m)(26.7 m)(9.4 m)(7 m)
USDFY, 2015FY, 2016

Cash

41 m37 m

Inventories

2.3 m2.1 m

Current Assets

151.1 m95.1 m

PP&E

676 k683 k

Total Assets

153.1 m96.8 m

Accounts Payable

157 k1.2 m

Current Liabilities

6.5 m8.4 m

Total Liabilities

11 m

Additional Paid-in Capital

260 m264 m

Retained Earnings

(117.4 m)(178.5 m)

Total Equity

142.8 m85.7 m

Financial Leverage

1.1 x1.1 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

63.3 m140.9 m39.1 m30.5 m28.5 m19 m

Current Assets

63.7 m164.2 m138.1 m118.1 m101.6 m86.8 m

PP&E

570.6 k573.5 k1.7 m2.6 m2.4 m646 k

Total Assets

66.5 m165.2 m141.3 m122.2 m105.5 m88.4 m

Accounts Payable

1.2 m693.8 k5.3 m5.1 m1.2 m1.5 m

Current Liabilities

5.9 m6.2 m10.9 m16.7 m8.6 m7.9 m

Additional Paid-in Capital

11.6 m257.9 m262.3 m262.7 m263.5 m264.8 m

Retained Earnings

(93.5 m)(102.9 m)(134.6 m)(161.3 m)(170.6 m)(185.5 m)

Total Equity

(81.9 m)155.3 m128.1 m101.8 m93.1 m79.4 m

Financial Leverage

-0.8 x1.1 x1.1 x1.2 x1.1 x1.1 x
USDFY, 2015FY, 2016

Net Income

(35.9 m)(61.1 m)

Depreciation and Amortization

201 k433 k

Accounts Receivable

(215 k)(215 k)

Inventories

(1.7 m)674 k

Accounts Payable

(161 k)1.8 m

Cash From Operating Activities

(33.3 m)(52 m)

Purchases of PP&E

(269 k)(3 m)

Cash From Investing Activities

(109.1 m)49 m

Long-term Borrowings

(11.1 m)

Cash From Financing Activities

143.3 m(1.1 m)

Interest Paid

921 k

Income Taxes Paid

69 k140 k
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.8 m)(9.4 m)(17.2 m)(26.7 m)(9.4 m)(7 m)

Accounts Payable

1.2 m693.8 k5.3 m5.1 m1.2 m1.5 m
Y, 2017

Financial Leverage

1.1 x

Chiasma Market Value History

Chiasma Online and Social Media Presence

Chiasma Company Life and Culture

You may also be interested in